Dapagliflozin

内容来自：环球财经网 为了尽快降低患者用药成本，享受集采的红利，新年伊始，全国各地医保局开始如火如荼地启动第十一批集采供应，各省患者也陆陆续续可以在当地医院开到集采价格的药品。 但是，近日广东各地的糖尿病患者却意外发现：自己长期在用的达格列净片，在医院出现缺货情形。 这款药在2025年10月被国家医保局集采，价格有了大幅度的下降，大家原来以为可以省钱了，现在却被告知“没货”，这让人多少有些郁闷。 据接近广州公共资源交易中心的人士透露：达格列净片广东省主供企业印度Hetero Labs Limited(以下简称“熙德隆”)，目前确实无法供货。 3月18日，湖南省医保局一纸通知(湘医保招采函【2026】23号)证实了这一消息：由于熙德隆不能及时足量供应达格列净片，省内医疗机构可以在所有中标企业中自行选择。 达格列净片是第十一批集采报量最高、竞争最激烈的品种。 作为国内首款上市的SGLT2抑制剂类药物，它不仅是2型糖尿病患者的一线用药，更因兼具心衰、慢性肾病等适应症受到广大医生患者的信赖和认可。 最终，包括2家印度药企和5家中国药企在内的7家企业中标，其中广东省主供企业正是以第一顺位超低价中标的熙德隆。 熙德隆充分展示了印度药企“价格屠夫”底色，把达格列净片的价格从4.36元/片直接杀到了0.215元/片的地板价。 但同时，它本身也引起了很多的争议。就在集采中标的两个月前，其被FDA发现存在诸多违反GMP的严重缺陷，仓库中还发现鸟巢、鸟粪与蜥蜴等动物污染源等匪夷所思的情形，被广大网友戏称为“鸟屎工厂”。 就在熙德隆为供货焦头烂额的同时，达格列净片集采中标的另一家印度企业Cipla(以下简称“西普拉”)，也因面临原研的专利诉讼而心烦意乱。 事实上，原研一直认为西普拉制剂的生产过程中使用了其专利晶型。就在集采开标前两周，原研针对专利(专利号：ZL201210201489.X)“含有达格列嗪丙二醇水合物的药物制剂”在上海起诉了西普拉。 西普拉中标后，原研在2025年12月就达格列净片的另一项专利(专利号：ZL200780024135.X)“作为用于治疗糖尿病的SGLT2抑制剂的(1S)-1，5-脱水-L-C-(3-((苯基)甲基)苯基)-D-葡萄糖醇衍生物与氨基酸的结晶溶剂合物和络合物”，又在南京起诉了其中国总经销商。 之后，西普拉于2026年2月11日迅速进行了一项备案，备案内容为：在本品说明书中增加注释：“活性成份在本品中以达格列净无定型形式存在。”个中情况，耐人寻味。 从2018年“4+7”试点开始的药品集采，极大地减轻了患者的用药成本和国家的医保支出，但也存在不足。 2025年，国家开始重新审视集采政策，并在国务院政府工作报告中十分罕见但又十分明确地提出“完善国家药品集中采购制度”，第十一批集采正是在此大背景下出台。 而其中，曾因“医保专家灵魂砍价”而闻名全国的超级重磅炸弹达格列净片，以其标志性的市场地位(目前以销售额超80亿元人民币雄踞中国医药市场小分子药物销售额第1位)再次成为万众瞩目的焦点。 最终，单品报量占了20%总量的达格列净片的中标价，并没有出现雪崩式的坍塌(除了熙德隆0.215元/片的最低价，中标价格主要在0.28-0.36元/片之间)，基本达到了“反内卷”的目标，也充分证明了新推出的“按厂牌报量”等规则的作用。 但从达格列净片中标和执标情况来看，目前的集采可能还存在两个隐患。如下： 其一，开放境外药企参与竞争，初衷是挖掘全球医药产业资源、为中国患者带来优质低价的好药，但核心前提是中标方能严格履约保供。 尽管集采一直坚持“中外药企一视同仁、同规则同处罚”的原则，但在实操层面，境外药企的跨境属性，让监管、保供、惩戒的落地管理难度远高于国内药企，熙德隆的缺货就是其中的一个缩影。 其二，达格列净片是集采开展以来，首个在专利保护期内或可能存在专利纠纷就进行集采的品种。集采开标前，本来有14家药企报名，但因为专利问题最终参与报价的却只有11家。 西普拉和原研的专利纠纷最终结果如何还不得而知，但它确实给集采提出了一个思考：存在专利风险的品种应不应该纳入集采?毕竟，出于自身利益的考量，厂家未必会对专利风险做出客观的评估；而专利本身是复杂的法律和技术问题，对其风险的判断也不是医保局的职能，但如果因为专利纠纷而最终导致断货，其影响却要医保局来承担，这本身就是个悖论。 缺货和诉讼都会对集采保供产生影响，但相信最终都会有解决办法。只是这个过程希望能尽可能短一点，毕竟最后直接影响的还是亟需临床用药的患者。 摩熵药筛小程序重磅改版，查询产品信息更快捷！ 国采续采交流群已建，加客服微信，入群交流！

HILLSBOROUGH, N.J.--(BUSINESS WIRE)--The Campaign for Personal Prescription Importation (CPPI), a non-profit advocate for affordable access to prescription medications, has released a new price comparison study highlighting the stark differences between U.S. and Canadian pharmacy prices for popular brand-name prescription drugs. We’re in an affordability epidemic. With the ability to personally import essentially identical medications from Canada, U.S. consumers can find desperately needed relief. Using data researched in Mar. 2026, CPPI’s analysis shows that for a sample of 10 popular, name-brand prescription medicines – all daily maintenance medications for common conditions – U.S. consumers can save 52% to 89% by purchasing from licensed Canadian online pharmacies. These results show personal importation from Canada continues to be a significant option for those facing exorbitantly high drug costs. America in a Drug “Affordability Epidemic” CPPI’s study underscores how U.S. prescription costs outpace affordability – as a great number of Americans are dangerously non-compliant with their drug therapy. For instance, a recent survey from the Kaiser Family Foundation (KFF) reveals that about one in five adults (21%) have not filled a prescription due to cost. Additionally, the KFF survey finds about one in seven adults say they have cut pills in half or skipped doses of medicine in the last year because of the cost. “These results highlight the ongoing need for easily accessible alternatives to notoriously high U.S. pharmaceutical prices. We’re in an affordability epidemic,” said CPPI’s Executive Director Ken Hunter. “Millions of Americans are on fixed incomes, have high-deductible health plans that skyrocketed in price when Affordable Care Act subsidies ended in December, or can’t afford insurance at all. With the ability to personally import essentially identical medications from Canada, consumers can find desperately needed relief.” CPPI’s findings, drawn from research comparing GoodRx and Amazon prices in the U.S. against Canadian equivalents, demonstrate average savings of over 64% across 10 commonly prescribed brand-name drugs. These include treatments for conditions including Type 2 diabetes, blood clots, and overactive bladder. Top savings examples for 90-day supplies include: Jublia (12 ml, antifungal): U.S. GoodRx price $2,236.00, U.S. Amazon price $2,502.10, Canadian pharmacy average $257.77 – 89% savings. Xifaxan (550 mg, treats IBS): U.S. GoodRx price $10,036.00, U.S. Amazon price $11,233.90, Canadian pharmacy average $2,325.78 – 78% savings. Myrbetriq (50 mg, treats overactive bladder): U.S. GoodRx price $1,129.00, U.S. Amazon price $994.78, Canadian pharmacy average $314.57 – 70% savings. Additional drugs researched in the study included Xarelto, Jardiance, Rybelsus, Farxiga, Trintellix, Premarin, and Eliquis. The full comparison chart of the 10 popular prescription medications is at https://shorturl.at/odDrW. "With U.S. drug prices being less affordable for millions, this study shows personal prescription importation from licensed Canadian pharmacies remains a proven lifeline that is available today," said Hunter. "Our data shows consumers can slash costs on essential brand-name medications, allowing them to prioritize health without financial ruin. This transforms lives, and Americans should know they have this safe, reliable option." For more information on safe importation and to join (for free) the fight for affordable medications, visit www.PersonalImportation.org. Methodology: Prices obtained Mar. 2026 for 90-day supplies. Amazon pricing is for delivery to N.J.; GoodRx pricing is from N.J. pharmacies using cash price with the lowest after-coupon discount price; Canadian mail-order pricing uses the average of a cross-section of pharmacies certified by Canadian International Pharmacy Assn. (CIPA.com) and is for Health Canada-approved, brand-name products dispensed by a pharmacy licensed in Canada. Savings based on average of GoodRx and Amazon prices. At time of survey, Rybelsus 7 mg was priced but unavailable at Amazon. All registered trademarks referred to herein belong to their respective owners. About CPPI: The Campaign for Personal Prescription Importation (CPPI), based in Hillsborough, N.J., is a national nonprofit patient advocacy organization fighting for Americans' access to safe, affordable prescription medications from Canada for personal use. Tens of millions of Americans – especially the elderly and others on fixed incomes – struggle to pay the extremely high prices of prescription medications in the U.S. CPPI is their voice. For more information and to join us: www.PersonalImportation.org.